The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. This year’s metric has recorded a Price increase of 10.81%. However, over the past six months, we’ve seen a stronger performance of -6.47%. The
A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Astrazeneca plc ADR’s current trading price is -16.68% away from its 52-week high, while its distance from the 52-week low is 16.41%. The stock’s
Astrazeneca plc ADR experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $87.68 on 08/30/24, while the lowest price for the same period was registered at $62.75 on 11/18/24. 52-week price history of AZN Stock Studying a
Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The metric has seen a significant gain of 14.07% since the start of this calendar year. Looking back over
The stock market performance of Astrazeneca plc ADR has been very steady. Over the last year, the company’s stock hit its highest at $87.68 on 08/30/24, while the lowest price during the same time frame was $62.75, recorded on 11/18/24. 52-week price history of AZN
Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The index has shown a price gain of 15.08% this year. Over the last six months, there has been
Astrazeneca plc ADR’s stock has seen a smooth market performance. The company’s stock achieved a 1-year high of $87.68 on 08/30/24, and the lowest price during that time was $62.75, recorded on 11/18/24. 52-week price history of AZN Stock A stock’s 52-week high and low
After the German government recommended its administration to people aged 18 to 64 years of age only, AstraZeneca plc (AZN) defended its vaccine’s effectiveness against the new coronavirus in the elderly. A spokesman for the British-Swedish group AstraZeneca plc (AZN) explained that the newest analysis
Pharma giant AstraZeneca plc (NASDAQ: AZN) pulled out of talks in Brussels in response to delays in the coronavirus vaccine delivery, a development that represents another escalation between the company and the European Union, as reported by Bloomberg. European Union officials have been pressuring the company
All rights reserved © 2024, Powered By Smart TechOne
